276 related articles for article (PubMed ID: 10804088)
1. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
Arastéh K; Hannah A
Oncologist; 2000; 5 Suppl 1():28-31. PubMed ID: 10804088
[TBL] [Abstract][Full Text] [Related]
2. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
Ellis LM; Takahashi Y; Liu W; Shaheen RM
Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
[TBL] [Abstract][Full Text] [Related]
4. VEGF receptor signaling in tumor angiogenesis.
McMahon G
Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
[TBL] [Abstract][Full Text] [Related]
5. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
Harris AL
Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089
[TBL] [Abstract][Full Text] [Related]
6. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
Verheul HM; Hoekman K; Jorna AS; Smit EF; Pinedo HM
Oncologist; 2000; 5 Suppl 1():45-50. PubMed ID: 10804091
[TBL] [Abstract][Full Text] [Related]
7. Kaposi's sarcoma cells of different etiologic origins respond to HIV-Tat through the Flk-1/KDR (VEGFR-2): relevance in AIDS-KS pathology.
Morini M; Benelli R; Giunciuglio D; Carlone S; Arena G; Noonan DM; Albini A
Biochem Biophys Res Commun; 2000 Jun; 273(1):267-71. PubMed ID: 10873597
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma.
Cornali E; Zietz C; Benelli R; Weninger W; Masiello L; Breier G; Tschachler E; Albini A; Stürzl M
Am J Pathol; 1996 Dec; 149(6):1851-69. PubMed ID: 8952523
[TBL] [Abstract][Full Text] [Related]
9. VEGF in brain tumors.
Machein MR; Plate KH
J Neurooncol; 2000; 50(1-2):109-20. PubMed ID: 11245271
[TBL] [Abstract][Full Text] [Related]
10. c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells.
Munshi N; Groopman JE; Gill PS; Ganju RK
J Immunol; 2000 Feb; 164(3):1169-74. PubMed ID: 10640727
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
12. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma.
Brown LF; Tognazzi K; Dvorak HF; Harrist TJ
Am J Pathol; 1996 Apr; 148(4):1065-74. PubMed ID: 8644848
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development.
Samaniego F; Markham PD; Gendelman R; Watanabe Y; Kao V; Kowalski K; Sonnabend JA; Pintus A; Gallo RC; Ensoli B
Am J Pathol; 1998 Jun; 152(6):1433-43. PubMed ID: 9626048
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
15. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
Tulpule A; Scadden DT; Espina BM; Cabriales S; Howard W; Shea K; Gill PS
J Clin Oncol; 2000 Feb; 18(4):716-23. PubMed ID: 10673512
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma.
Masood R; Cai J; Zheng T; Smith DL; Naidu Y; Gill PS
Proc Natl Acad Sci U S A; 1997 Feb; 94(3):979-84. PubMed ID: 9023368
[TBL] [Abstract][Full Text] [Related]
17. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G
Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193
[TBL] [Abstract][Full Text] [Related]
18. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis inhibition in solid tumors.
Rosen LS
Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells.
Nakamura S; Murakami-Mori K; Rao N; Weich HA; Rajeev B
J Immunol; 1997 May; 158(10):4992-5001. PubMed ID: 9144519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
